enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Lifileucel - Wikipedia

    en.wikipedia.org/wiki/Lifileucel

    Lifileucel is the first tumor-derived T cell immunotherapy approved by the US Food and Drug Administration (FDA). [3] It was approved for medical use in the United States in February 2024. [ 2 ] [ 4 ]

  3. Mavorixafor - Wikipedia

    en.wikipedia.org/wiki/Mavorixafor

    Mavorixafor improved absolute neutrophil counts and absolute lymphocyte counts, assessed over a 24-hour period four times throughout the study. [2] Absolute neutrophil counts below 500 cells/μL and absolute lymphocyte counts below 1000 cells/μL are associated with an increased risk of infections. [ 2 ]

  4. Tisagenlecleucel - Wikipedia

    en.wikipedia.org/wiki/Tisagenlecleucel

    In July 2017, an FDA advisory committee unanimously recommended that the agency approve it to treat B cell acute lymphoblastic leukemia that did not respond adequately to other treatments or have relapsed. [14] [19] [20] In August 2017, the FDA granted approval for the use of tisagenlecleucel in people with acute lymphoblastic leukemia.

  5. Immunotherapy - Wikipedia

    en.wikipedia.org/wiki/Immunotherapy

    The first FDA-approved cell-based immunotherapy, ... Lymphocyte proliferation is the multiplication of lymphocyte cells used to fight and remember foreign invaders. ...

  6. Iovance Biotherapeutics - Wikipedia

    en.wikipedia.org/wiki/Iovance_Biotherapeutics

    In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma. [4]

  7. 2 Innovative Stocks That Could Deliver Outsize Returns - AOL

    www.aol.com/2-innovative-stocks-could-deliver...

    The company develops therapies based on tumor-infiltrating lymphocytes (TILs). ... Iovance earned approval from the U.S. Food and Drug Administration for Amtagvi, the first therapy for advanced ...

  8. Bi-specific T-cell engager - Wikipedia

    en.wikipedia.org/wiki/Bi-specific_T-cell_engager

    Talquetamab was approved for medical use in both the United States [9] [13] [14] and the European Union [15] in August 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .

  9. The FDA approved the US’ first over-the-counter birth control ...

    www.aol.com/fda-approved-us-first-over-105728509...

    The US Food and Drug Administration has approved the oral contraceptive Opill for over-the-counter use, making it the first nonprescription birth control pill in the United States.